|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0087111,
umls-concept:C0246415,
umls-concept:C0332281,
umls-concept:C0376259,
umls-concept:C0441767,
umls-concept:C0717726,
umls-concept:C0728747,
umls-concept:C0920321,
umls-concept:C1516213,
umls-concept:C2603343
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-2-27
|
|
pubmed:abstractText |
We carried out a phase I clinical trial to establish the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of the combination of liposome-encapsulated doxorubicin citrate (LD) and docetaxel in breast cancer patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
454-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19074216-Adult,
pubmed-meshheading:19074216-Antibodies, Monoclonal,
pubmed-meshheading:19074216-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19074216-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19074216-Breast Neoplasms,
pubmed-meshheading:19074216-Cohort Studies,
pubmed-meshheading:19074216-Doxorubicin,
pubmed-meshheading:19074216-Female,
pubmed-meshheading:19074216-Genes, erbB-2,
pubmed-meshheading:19074216-Humans,
pubmed-meshheading:19074216-Liposomes,
pubmed-meshheading:19074216-Middle Aged,
pubmed-meshheading:19074216-Taxoids
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.
|
|
pubmed:affiliation |
Hospital Universitario Miguel Servet, Zaragoza, Spain. aantont@salud.aragon.es
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I
|
